A detailed history of Pacer Advisors, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 622 shares of RNA stock, worth $25,352. This represents 0.0% of its overall portfolio holdings.

Number of Shares
622
Previous 931 33.19%
Holding current value
$25,352
Previous $23,000 8.7%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$22.73 - $40.85 $7,023 - $12,622
-309 Reduced 33.19%
622 $25,000
Q1 2024

May 10, 2024

BUY
$9.16 - $25.52 $8,527 - $23,759
931 New
931 $23,000
Q2 2021

Jul 21, 2021

SELL
$19.62 - $29.26 $27,801 - $41,461
-1,417 Closed
0 $0
Q1 2021

Apr 05, 2021

BUY
$20.28 - $28.15 $11,721 - $16,270
578 Added 68.89%
1,417 $31,000
Q4 2020

Jan 20, 2021

BUY
$24.73 - $35.12 $20,748 - $29,465
839 New
839 $21,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.12B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.